跳至主要内容
临床试验/NCT06283082
NCT06283082已完成不适用

Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) Gene - Influence of Hygienic and Dietary Conditions and Identification of Favouring Factors by Comparison of Asymptomatic and Symptomatic Patients (Lithiasis or Oxalic Nephropathy)

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年12月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
2
主要终点
Urinary oxalate and glycolate excretion

研究概览

简要总结

Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure. PH1 is linked to a deficiency in glyoxylate amino transferase (AGXT), which leads to increased endogenous oxalate synthesis and hyperoxaluria. In the urine, urinary oxalate precipitates with calcium, forming insoluble crystals, leading to lithiasis and the development of nephrocalcinosis.

Non-genetic etiologies of oxalic nephropathy are well known, in particular enteric causes (malabsorptions, bypass, calcium deficiencies, etc.) and sometimes linked to increased oxalate intake in the form of nutritional or vitamin supplements, reinforcing the hypothesis of probably underestimated favouring factors of hyperoxaluria.

Until now, heterozygous patients with a mutation in the AGXT gene were considered asymptomatic. However, there have been several cases of patients with heterozygous AGXT mutations presenting with lithiasis.

Consequently, the characteristics of symptomatic and asymptomatic heterozygous patients will be studied in order to define the elements that would explain the expression of the disease (particularities of the AGXT mutation, presence of another heterozygous mutation or favorable living conditions).

The hypothesis is that there is an increase in hepatic oxalate production in heterozygous patients, which explains why they remain asymptomatic under usual conditions, but could favor stone formation under favorable conditions such as severe calcium deficiency or malabsorption.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Presenting an heterozygous mutation on AGXT
  • Presenting symptoms (presence or history of stones, nephrocalcinosis) or not

排除标准

  • Individuals unable to provide 24-hour urine samples.
  • Individuals unable to free up a morning for day hospital appointments
  • Individuals deprived of liberty by a judicial or administrative decision.
  • Adults under a legal protection measure (guardianship, trusteeship).
  • Individuals placed under judicial protection.
  • Participants enrolled in another study with an ongoing exclusion period
  • Pregnant women.
  • Individuals not covered by social security

研究组 & 干预措施

Asymptomatic subjects with an AGXT heterozygous mutation

Experimental

干预措施: Lithiasis assessment (Diagnostic Test)

Symptomatic subjects with an AGXT heterozygous mutation

Active Comparator

干预措施: Lithiasis assessment (Diagnostic Test)

结局指标

主要结局

Urinary oxalate and glycolate excretion

时间窗: At Day 0

Comparison of urinary oxalate and glycolate excretion expressed in mmol/L and mmol/24h of symptomatic versus asymptomatic heterozygous AGXT subjects.

次要结局

  • Predisposing conditions for lithiasis disease(At Day 0)
  • The prevalence of stones(At Day 0)
  • Lithiasis disease severity(At Day 0)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验